Veradermics Inc
NYSE:MANE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Veradermics Inc
NYSE:MANE
|
US |
|
W
|
Wave Electronics Co Ltd
KOSDAQ:095270
|
KR |
Veradermics Inc
Veradermics Inc is a US-based company operating in industry. The company is headquartered in New Haven, Connecticut. The company went IPO on 2026-02-04. Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The firm is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The firm is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The firm is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Veradermics Inc is a US-based company operating in industry. The company is headquartered in New Haven, Connecticut. The company went IPO on 2026-02-04. Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The firm is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The firm is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The firm is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
